|Description||Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. It improves red blood cell deformability, reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. It also reduces AST and ALT levels and may improve liver histological scores in patients with NALFD/NASH, but did not appear to affect cytokines.|
|Synonyms||Trental; PTX; Oxpentifylline|
PF 04449613 is a potent PDE9 inhibitor (IC50 = 22 nM), and also shows a high affinity for cGMP (Km ~170 nM). Some studies suggest that elevating the level of cG...
RVT-501, also referred to E6005, is a selective phosphodiesterase 4 (PDE4) inhibitor (IC50= 2.8 nM) with potential effect to treat atopic dermatitis.
BAY 73-6691 is a phosphodiesterase inhibitor selective for the PDE9A subtype under the development of Bayer. It selectively inhibits human PDE9 with IC50 value ...
ITI214 is a highly selective PDE1 inhibitor (Ki = 58 pM) at picomolar concentration without disrupting other PDE family members and a panel of enzymes, receptor...
Tadalafil binds to PDE5 with KD of 2.4 nM.
BC 11-38 is a potent and selective phosphodiesterase (PDE) 11 inhibitor (IC50 = 0.28 μM for PDE11; IC50 values are >100 μM for PDE1 - PDE10). BC 11-38 increases...
CP-461 free base
CP 461, belonging to a class of novel proapoptotic drugs with antineoplastic effect, specifically inhibit cyclic GMP phosphodiesterases but not cyclooxygenase-1...
Vesnarinone, a quinolinone derivative, is a cardiotonic agent. It has pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, incre...